At a glance
- Originator AstraZeneca
- Class Antiarrhythmics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 06 Sep 2000 Discontinued-Preclinical for Arrhythmias (Unknown route)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
- 28 Aug 1997 New profile